Biotech | March 03, 2022
Medix Biochemica announces expansion of its porfolio
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
